Form 4: Serina Therapeutics Director Acquires Convertible Preferred Stock

Jay Venkatesan, a director of Serina Therapeutics, acquired Series A Convertible Preferred Stock on April 8, 2025.

Summary

• On April 8, 2025, Jay Venkatesan, a director of Serina Therapeutics, acquired 96,525 shares of Series A Convertible Preferred Stock.
• The conversion price for the Series A Convertible Preferred Stock is $5.18.
• These shares are held indirectly through The Jay Venkatesan Legacy Trust.
• The Series A Convertible Preferred Stock converts into Common Stock, $0.0001 par value.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a change in beneficial ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

This filing reflects a change in beneficial ownership by a company insider, which is a common occurrence. The market often interprets insider transactions as a signal of management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of preferred stock by a director could be viewed positively by shareholders as it may indicate confidence in the company's future performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Series A Convertible Preferred Stock, Serina Therapeutics, Director, Jay Venkatesan